von der Ohe M R, Camilleri M, Thomforde G M, Klee G G
Gastroenterology Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.
Gut. 1995 May;36(5):743-8. doi: 10.1136/gut.36.5.743.
The effects of octreotide on regional motor function in the human gut are unclear. In a randomised, blinded study the effects of octreotide (50 micrograms, subcutaneously, three times daily) and placebo on gastric, small bowel, and colonic transit, and colonic motility and tone were assessed in 12 healthy volunteers whose colon had been cleansed. Octreotide accelerated initial gastric emptying (p = 0.05), inhibited small bowel transit (p < 0.01), and reduced ileocolonic bolus transfers (p < 0.05). Colonic transit was unaltered by octreotide; the postprandial colonic tonic response was inhibited (p < 0.05 v placebo), whereas colonic phasic pressure activity was increased by octreotide (p < 0.05 v placebo). These data support the use of octreotide in diarrhoeal states but not in diseases that cause small bowel stasis and bacterial overgrowth. Simultaneous measurements of colonic transit, tone, and phasic contractility are valid in studying the effects of pharmacological changes and may be applicable to the study of the human colon in health and disease.
奥曲肽对人体肠道局部运动功能的影响尚不清楚。在一项随机、双盲研究中,对12名结肠已清洁的健康志愿者评估了奥曲肽(50微克,皮下注射,每日三次)和安慰剂对胃、小肠和结肠转运以及结肠动力和张力的影响。奥曲肽加速了初始胃排空(p = 0.05),抑制了小肠转运(p < 0.01),并减少了回结肠团块转移(p < 0.05)。奥曲肽未改变结肠转运;餐后结肠紧张性反应受到抑制(与安慰剂相比,p < 0.05),而结肠的阶段性压力活动因奥曲肽而增加(与安慰剂相比,p < 0.05)。这些数据支持奥曲肽用于腹泻状态,但不支持用于导致小肠淤滞和细菌过度生长的疾病。同时测量结肠转运、张力和阶段性收缩性对于研究药理变化的影响是有效的,并且可能适用于健康和疾病状态下人体结肠的研究。